ALT Stock: H.C. Wainwright Maintains Buy Rating, May 2026

H.C. Wainwright maintained its Buy rating on Altimmune (ALT) on May 18, but trimmed its price target to $20 from $25. The ALT stock rating adjustment reflects cautious optimism about the clinical-stage biotech’s obesity and liver disease pipeline. Shares trade at $2.80, down 1.75% on the day. We examine what this maintained rating means for investors tracking this healthcare stock.

H.C. Wainwright Maintains Buy Despite Price Target Cut

H.C. Wainwright kept its Buy rating intact while lowering the ALT stock rating price target by 20%. The analyst firm’s decision signals confidence in Altimmune’s long-term potential despite near-term headwinds. The price target reduction to $20 from $25 suggests the path to profitability may take longer than previously expected.

Altimmune trades at $2.80, well below the new $20 target. The stock has declined 49% over the past year and 80% over five years. Current analyst consensus shows 4 Buy ratings and 3 Hold ratings among tracked firms. Meyka AI rates ALT with a grade of B, reflecting mixed fundamentals and sector headwinds.

Clinical Pipeline Drives Long-Term ALT Stock Rating Outlook

Altimmune’s lead candidate pemvidutide targets obesity and non-alcoholic steatohepatitis in Phase 1b trials. The GLP-1/glucagon dual receptor agonist represents the company’s primary value driver. HepTcell, an immunotherapy for chronic hepatitis B, progresses through Phase 2 testing.

The biotech operates with 59 employees and maintains a $247 million market cap. Cash per share stands at $2.66, providing runway for clinical development. However, negative earnings per share of -$0.92 and negative free cash flow highlight the pre-revenue stage challenges facing this ALT stock rating environment.

Financial Metrics Show Pre-Revenue Biotech Dynamics

Altimmune’s financial profile reflects typical clinical-stage biotech characteristics. The company reports negative net income, negative operating cash flow, and negative free cash flow. Return on equity sits at -42.6%, while return on assets measures -27.1%.

Stock trades above its 50-day average of $3.24 and 200-day average of $3.98. The current ratio of 29.6 indicates strong liquidity for funding operations. Debt-to-equity ratio of 0.13 shows conservative leverage. These metrics support the maintained Buy rating despite execution risks in clinical trials.

Analyst Consensus and Meyka Grade Assessment

Four analysts rate ALT as Buy while three maintain Hold positions. No Sell or Strong Sell ratings exist in current coverage. Meyka AI’s proprietary grading system assigns ALT a B grade based on S&P 500 benchmarking, sector performance, financial growth, key metrics, and analyst consensus.

This grade factors in the company’s strong cash position against negative profitability metrics. The B rating suggests moderate risk-adjusted potential. These grades are not guaranteed and we are not financial advisors. Earnings announcement is scheduled for August 11, 2026, which may trigger volatility in the ALT stock rating.

Final Thoughts

H.C. Wainwright’s maintained Buy rating on ALT reflects confidence in Altimmune’s clinical pipeline despite the 20% price target reduction. The biotech’s obesity and hepatitis B programs represent significant long-term opportunities, but execution risk remains high. With $2.66 cash per share and strong liquidity, the company has runway to advance trials. Investors should monitor Phase 1b and Phase 2 trial progress closely. The ALT stock rating environment remains speculative, suitable only for risk-tolerant portfolios tracking clinical-stage biotechs.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.